How Much Does Retatrutide Cost? (2026)

Retatrutide draws more cost searches than almost any other emerging weight-loss drug, and for a specific reason: Phase 2 trial data published in the New England Journal of Medicine showed 24.2% average body weight loss over 48 weeks at the highest dose — a number that had not been seen in a controlled trial before it.⁴ Then Phase 3 TRIUMPH-1 results released in May 2026 extended that to 28.3% average weight loss over 80 weeks at the 12 mg dose (roughly 70.3 lbs on average).³ People who have seen those numbers want to know what it would cost to access this drug. The answer is more complicated than a single price, because the drug does not officially have one yet.

This guide breaks down every current access route, the pricing reality at each tier, what the regulatory timeline means for future costs, and the honest limits of what anyone can tell you about retatrutide prices at this stage of development.

Why retatrutide has no official price

A drug can only have a manufacturer list price after the FDA approves it for commercial sale. Retatrutide — Eli Lilly's investigational triple-hormone-receptor agonist, internal code LY3437943 — has not received FDA approval for any condition as of September 2026. It remains in Phase 3 clinical trials under Lilly's TRIUMPH program, which is studying retatrutide across obesity, type 2 diabetes, cardiovascular outcomes, and several other indications.³

Until a New Drug Application (NDA) is submitted and reviewed, there is no branded product, no pharmacy price, no insurance billing code, and no manufacturer savings program. The pricing figures you see on third-party sites for "retatrutide" are estimates, gray-market research vendor quotes, or speculation about post-approval pricing — not a price list from Eli Lilly.

The FDA's drug approval process requires a company to demonstrate, through clinical trial data, that a drug's health benefits outweigh its known risks before it can be marketed and sold.¹ Retatrutide has received Fast Track designation from the FDA, which facilitates more frequent agency communication and can accelerate the review process once an NDA is filed — but it does not change the fundamental requirement that the process must complete before any price exists.

The four access routes and their costs

1. Clinical trial enrollment — the only no-cost option

Participants in Eli Lilly's TRIUMPH Phase 3 program receive retatrutide at no charge, including all study medication, monitoring, laboratory work, and related care. TRIUMPH-1, the primary obesity trial, enrolled 2,339 participants across multiple sites and randomized them to receive either retatrutide at 4 mg, 9 mg, or 12 mg once weekly, or placebo.³

The practical limitation by September 2026 is that most TRIUMPH enrollment is complete. TRIUMPH-1 completed its main 80-week study phase, and extension enrollment has closed. Sub-studies, extension trials for other indications (sleep apnea, cardiovascular disease, type 2 diabetes), and newly opened trials in the broader program may still be recruiting. You can search ClinicalTrials.gov for the TRIUMPH program⁵ to find currently active enrollment opportunities, but for most people interested in retatrutide, this window has mostly passed.

2. Research-grade vendors — the current gray-market reality

The only commercial access to retatrutide in 2026 is through US-based research peptide vendors, who sell it labeled "for research use only" with no prescription required. These products are not FDA-approved medications. They exist in a legal gray zone based on a regulatory distinction between drugs intended for human therapeutic use (which require approval) and compounds sold for laboratory research purposes.

Typical pricing across established vendors in September 2026:

• 10 mg vial: approximately $70–$85 per vial, or about $7–$8.50 per milligram
• 30 mg vial: approximately $160–$180 per vial, or about $5.50–$6 per milligram
• 60 mg vial: approximately $220–$240 per vial, or about $3.50–$4 per milligram (where available)

Monthly cost depends on dose. At a conservative starting level (approximately 8 mg per month based on Phase 2 low-dose protocols), a single 10 mg vial covers roughly five to six weeks, bringing the monthly equivalent to $50–$70. At a moderate dose level (approximately 16 mg per month), monthly cost rises to approximately $100–$140. These are per-vial costs only and exclude any physician involvement, laboratory testing, or medical monitoring — which the gray-market model does not provide.

The gap between research-grade and pharmaceutical-grade products is real. Without independent third-party testing on each batch, there is no reliable way for a purchaser to verify purity, potency, or sterility. Certificates of analysis vary widely in their legitimacy — from genuine independent HPLC and mass spectrometry reports to documents generated by the same facility that produced the peptide, which is a different thing entirely.

3. Compounding pharmacies — legally complicated

Some patients ask whether a licensed compounding pharmacy can produce retatrutide from the active pharmaceutical ingredient, allowing prescription access at a lower cost than an eventual branded product. The answer involves important regulatory context.

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies can prepare medications based on a physician's prescription, typically when a patient needs a specific formulation that isn't commercially available or when a shortage exists of an approved product. The key constraint is that the FDA's compounding framework is built around approved drugs — either compounding from an approved reference product or from bulk drug substances that appear on the FDA's 503A list.⁶

Retatrutide is not FDA-approved and does not appear on the 503A bulk drug substance list. This means a pharmacy that compounds retatrutide is operating outside the standard regulatory framework for compounding — sourcing the active ingredient through channels the FDA has not reviewed or sanctioned for human use. Some licensed telehealth providers are offering it through 503A pharmacies at reported cash prices of approximately $250–$600 per month, but this arrangement carries different risks than compounding an approved drug like tirzepatide or semaglutide.

Whether that arrangement is appropriate for any individual patient is a conversation to have with a licensed physician and a licensed pharmacist who can confirm their current regulatory posture — not a cost calculation to make from a comparison table.

4. Branded retatrutide after FDA approval — projected costs

Eli Lilly has not announced an NDA submission date, but TRIUMPH-1 Phase 3 data has read out successfully and additional data from TRIUMPH-2 (type 2 diabetes) and other indications is expected through 2026 and 2027. Regulatory analysts generally model an NDA submission in late 2026 or the first half of 2027, with a typical FDA review period of 6–12 months following a complete submission.¹

For projected pricing, the most useful reference points are Eli Lilly's own precedents. Zepbound (tirzepatide), the only other Lilly-developed GLP-1 class drug approved for obesity, launched in late 2023 at a list price of approximately $1,059 per month.² Wegovy (semaglutide) from Novo Nordisk launched at approximately $1,349 per month. Dr. John Sharretts, M.D., director of the FDA's Division of Diabetes, Lipid Disorders, and Obesity, stated at Zepbound's approval: "Obesity and overweight are serious conditions that can be associated with some of the leading causes of death such as heart disease, stroke and diabetes" — underscoring why regulators and drug developers treat this drug class as addressing a serious unmet need that commands premium pricing.²

Based on these precedents, most analysts project retatrutide will launch somewhere in the $1,000–$1,350 per month range at list price. Lilly may attempt to price it modestly above Zepbound if Phase 3 data supports a superior efficacy argument; they may also keep it in range to avoid triggering aggressive payer resistance. Either way, the uninsured cash price is expected to be substantially higher than current research-grade vendor pricing.

Retatrutide cost comparison: all access routes

What determines cost more than any other factor

FDA approval status

Everything else in this guide flows from one fact: retatrutide is not FDA-approved. That single status determines that there is no manufacturer price, no insurance billing code, no compounding reference product, and no pharmacy that can legally dispense it as a standard prescription medication. Every cost figure above is either an estimate of what may come or a description of gray-market channels that exist specifically because the approved product does not.

Dose level

In TRIUMPH-1, Eli Lilly studied three doses: 4 mg, 9 mg, and 12 mg once weekly. Higher doses showed greater efficacy — participants at 12 mg lost an average of 28.3% of body weight over 80 weeks, while those at 4 mg lost an average of 19.0%.³ For post-approval pricing, Lilly will likely follow the same tiered approach used with Zepbound, where lower starting doses are available at lower prices and patients titrate up. A patient eventually maintained at a lower dose will pay less per month than one at the maximum.

Insurance coverage and indication

Commercial insurance coverage for GLP-1 class obesity drugs is inconsistent even for already-approved medications. Many plans cover Wegovy and Zepbound with prior authorization for patients meeting BMI and comorbidity thresholds; many others do not cover them for obesity at all, though they may cover the same drug under a diabetes indication. Medicare Part D is currently prohibited by statute from covering anti-obesity medications, though this may change legislatively, and limited carve-outs exist for cardiovascular indications.

After retatrutide approval, coverage decisions will likely mirror what happened with tirzepatide: heavy adoption where employers opted into obesity coverage, patchy coverage elsewhere, and essentially no Medicare Part D coverage for obesity unless the law changes. If approved for type 2 diabetes (the TRIUMPH-2 indication), Medicare Part D coverage for that indication would likely follow the pattern established for Mounjaro.

Manufacturer savings programs

Eli Lilly offers Zepbound at reduced cost to commercially insured patients through a savings card program. A similar program is expected for retatrutide after launch, potentially making the drug accessible for as little as $25–$100 per month for eligible commercially insured patients, subject to income limits, insurance type restrictions, and program terms. These programs do not apply to uninsured patients, Medicare or Medicaid beneficiaries, or patients paying cash.

How the Phase 3 data shapes the pricing conversation

The clinical data from TRIUMPH-1 is the single most important input to understanding where retatrutide is likely to be priced and whether any insurer will cover it. The 28.3% average weight loss at 80 weeks surpasses what tirzepatide showed at the equivalent timepoint (approximately 20.9% at 72 weeks in SURMOUNT-1). The 4 mg dose, which requires only a single escalation step from the starting 2 mg dose, still produced 19.0% average weight loss — which matters for tolerability-driven conversations with payers about lower-dose access.

Additionally, 65.3% of participants on the 12 mg dose achieved a BMI below 30 — falling out of the obesity classification — after 80 weeks, and 45.3% achieved at least 30% weight loss, a level historically associated with bariatric surgery outcomes.³ These are the kinds of outcomes data that support a higher launch price; they are also the kind of data that can accelerate insurance formulary consideration because the per-unit efficacy argument is strong.

None of this changes the current access reality. A drug with impressive Phase 3 data is still not an approved drug. Until the FDA acts on an NDA, there is no legal commercial product, and any money spent on "retatrutide" goes to unapproved products in channels the FDA has not reviewed.

What this page cannot tell you

This guide covers publicly available pricing information and evidence-based projections. It cannot tell you whether retatrutide is appropriate for your situation, when Eli Lilly will file an NDA, how the FDA will respond, or what your specific insurance plan will cover. Those questions require a licensed physician, your insurance benefits department, and updated public information from Eli Lilly and the FDA as the approval process progresses.

For the evidence on what retatrutide actually is and what the clinical trials show, see our retatrutide evidence review. For the broader context of how peptides work and what distinguishes them from approved drugs, our guide to peptides is the right foundation. And for a side-by-side comparison of how peptide-adjacent drugs like retatrutide compare to current approved obesity medications, see our peptides for weight loss guide.

The question of what retatrutide costs is inseparable from where it is in its regulatory timeline. In 2026, the honest answer is: there is no approved price, and the gap between what gray-market research vendors charge now and what a branded post-approval product will cost is significant. Anyone budgeting for retatrutide should understand which side of that gap they are considering — and everything that is different between them.